Health

Only Nigerians earning above N2.5m annually can sustain diabetes treatment, study finds

Nigerians earning below N2.5 million annually may struggle to sustain diabetes treatment without falling into debt, highlighting the growing financial burden of managing chronic diseases in a country where millions of people remain undiagnosed.

Advertisement

Kingsley Aguoru, managing director of Colexa Biosensor, disclosed this to BusinessDay, citing a study conducted by Development Governance International Consult (DGI Consult), with support from Gatefield, which examined the impact of inflation on access to antidiabetic medicines across Nigeria.

According to Aguoru, the study compared average household incomes with the annual cost of diabetes management and found that only people earning above N2.5 million annually could afford consistent treatment without falling into debt.

The findings underscore the financial difficulties confronting Nigerians living with diabetes, a chronic condition that requires continuous medication, regular medical consultations, diagnostic tests and blood glucose monitoring.

Unlike illnesses that may require short-term treatment, diabetes management involves recurring expenses throughout a patient’s lifetime. These include antidiabetic medicines, insulin where necessary, glucose monitoring devices, test strips and routine medical assessments.

For households already struggling with rising living costs, the financial demands of managing the condition can create difficult choices between healthcare and other essential expenses.

According to estimates from the International Diabetes Federation (IDF), approximately 2.99 million Nigerian adults aged 20 to 79 were living with diabetes in 2024. However, an estimated 78.7 percent of these cases were undiagnosed, suggesting that a significant proportion of people may be unaware of their condition.

Other estimates indicate a substantially higher burden. A systematic review and meta-analysis published in ‘Cardiovascular Diabetology’ estimated the prevalence of Type 2 diabetes in Nigeria at seven percent, translating to approximately 8.02 million adults.

The Diabetes Association of Nigeria has also cited estimates ranging from 8.2 million to 11.04 million people living with the condition.

Despite differences in the estimates, the figures point to a substantial public health challenge, particularly when considered alongside the financial requirements of managing the disease.

Read also: Why we are building Nigeria’s healthcare economy

Cost of monitoring adds to treatment burden

Beyond purchasing antidiabetic medicines, people living with diabetes must regularly monitor their blood glucose levels to understand how their bodies respond to food, physical activity and medication.

Blood glucose monitoring involves measuring the amount of sugar in the blood, usually through a small blood sample obtained by pricking a finger and applying it to a compatible test strip.

The process helps patients identify unusually high or low blood glucose levels and enables healthcare professionals to make informed decisions about treatment.

However, maintaining regular monitoring requires access to a compatible glucose meter, test strips and other consumables, creating recurring expenses for patients.

For people who depend on imported medical products, fluctuations in exchange rates, import costs and supply chain disruptions can further complicate access to these essential monitoring tools.

The cost of replacing test strips, in particular, can become a significant financial commitment for individuals who need frequent testing. This means that even when patients can afford to purchase a glucose meter initially, the recurring cost of consumables may affect their ability to monitor their condition consistently.

The financial implications extend beyond individual patients to households, where the cost of managing diabetes competes with other essential expenses, including food, housing, education and transportation.

Undiagnosed cases complicate Nigeria’s diabetes response

The affordability challenge is compounded by gaps in screening and diagnosis.

Diabetes can develop without obvious symptoms in its early stages, meaning some people only discover they have the condition after complications have emerged.

Common symptoms include frequent urination, excessive thirst, unexplained weight changes and persistent fatigue. However, these signs may be overlooked or attributed to other health conditions.

Urbanisation and changing lifestyles are also contributing to the growing risk of Type 2 diabetes. Reduced physical activity, prolonged periods of sitting, increased consumption of processed foods and sugar-sweetened beverages, alongside genetic susceptibility and excess body weight, can increase the likelihood of developing the condition.

Unlike Type 1 diabetes, which is an autoimmune condition requiring lifelong insulin administration, Type 2 diabetes is primarily characterised by insulin resistance and accounts for approximately 90 to 95 percent of diabetes cases globally.

The IDF estimates that 24.6 million adults in Africa were living with diabetes in 2024, with approximately 73 percent unaware of their condition.

For Nigeria, the combination of undiagnosed cases and the high cost of treatment creates a double challenge: identifying people living with diabetes early enough and ensuring they can afford the care required to manage it.

Read also: How Solayo Africa is simplifying Nigeria’s maternal healthcare story

Local manufacturing emerges as part of the solution

As healthcare costs rise and dependence on imported medical products continues to expose patients to supply and affordability pressures, local manufacturing is increasingly becoming part of the conversation about improving access to essential healthcare products.

Aguoru said developing domestic capacity to manufacture medical devices could help strengthen supply chains and improve the availability of essential products required for long-term disease management.

Nigeria’s healthcare industrialisation agenda, driven partly through the Federal Ministry of Health and Social Welfare and the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), seeks to attract investment into domestic production of medicines, diagnostics and medical devices.

The initiative is expected to strengthen local manufacturing capacity, improve healthcare supply chains and reduce the country’s dependence on imported essential medical products.

Colexa Biosensor is among the Nigerian companies operating in this space, producing blood glucose monitoring solutions through its OnPoint blood glucose monitoring system.

The development of locally manufactured glucose monitoring devices presents an opportunity to expand domestic supply options for people living with diabetes, particularly those who require regular blood glucose testing.

However, local production alone does not automatically guarantee affordability. The availability, quality, distribution and cost of compatible test strips and other consumables will remain important considerations in determining whether locally manufactured devices can improve access for patients.

For the benefits of local manufacturing to reach households, domestic producers will also need an enabling environment that supports investment, production capacity, quality assurance and wider distribution.

Ultimately, Nigeria’s diabetes challenge requires more than awareness campaigns and medical interventions. It demands a healthcare system capable of identifying cases early, making treatment affordable and ensuring that essential medicines and monitoring devices remain accessible throughout a patient’s lifetime.

The N2.5 million annual income threshold cited by Aguoru underscores the financial pressures facing people living with diabetes and raises broader questions about how many Nigerians can realistically sustain the treatment they need.

As the country marks World Diabetes Day, the challenge is no longer simply about encouraging Nigerians to understand the disease, but about building a healthcare system in which a diabetes diagnosis does not become a long-term financial crisis.

Royal Ibeh

Royal Ibeh is a senior journalist with years of experience reporting on Nigeria’s technology and health sectors. She currently covers the Technology and Health beats for BusinessDay newspaper, where she writes in-depth stories on digital innovation, telecom infrastructure, healthcare systems, and public health policies.

Add BusinessDay as a preferred source on Google

Follow BusinessDay on Google News

Related Articles

Back to top button